草分枝杆菌膀胱灌注预防膀胱癌复发的临床研究  

Clinical research of intravesical instillation therapy with mycobacterium phlei against superficial bladder tumor for the prevention of the postoperative recurrence

作　　者：卢德祥[1] 牛颜良[1] 程险峰[1] 孙大鹏[1] 亢渐[1] 

机构地区：[1]黑龙江省医院泌尿外科,哈尔滨150001

出　　处：《临床泌尿外科杂志》2007年第2期134-135,共2页Journal of Clinical Urology

摘　　要：目的:探讨草分枝杆菌膀胱灌注预防浅表性膀胱肿瘤复发的临床疗效。方法:将浅表性膀胱癌术后患者60例随机分为草分枝杆菌灌注疗法组和卡介苗灌注疗法组,各30例。灌注前和灌注后1个月分别采血测定患者自然杀伤细胞(NK细胞),CD4+/CD8+比值,观察其值并比较分析。结果:患者进行草分枝杆菌灌注疗法组NK细胞,CD4+/CD8+比值明显高于卡介苗灌注疗法组。结论:草分枝杆菌膀胱内灌注防治膀胱癌无全身毒副作用,提高患者的免疫功能,可以减少膀胱癌的复发率。Objective.. To evaluate the immunotherapeutic efficacy of Mycobacterium Phlei against superficial bladder cancer for the prevention of the postoperative recurrence by intravesical instillation. Methods：A total of 60 patients following operation of superficial bladder cancer were equally randomized into two groups：one intravesical instillation group with Mycobacterium Phle,the other group with BCGo The number of natural kill cells（NK cells） and the ratio of CD4^ ＋/CD8^ ＋ were observed and analyzed in both groups. Results：The number of NK cells and the ratio of CD4^ ＋/CD8^ ＋ in the intravesical instillation group with Mycobacterium Phlei are much bigger than the group with BCG. Conclusions： The therapy of Mycobacterium Phlei through intravesical infusion was less side effect, improve the immune function and decrease recurrence of superficial bladder cancer.

关 键 词：膀胱肿瘤 膀胱内灌注 草分枝杆菌药物 

分 类 号：R737[医药卫生—肿瘤]